diabetic retinopathy
Conditions
Interventions
Add each treatment for 6 months. 1) vildagliptin 50 or 100mg/day
2) other oral hypoglycemic drugs except anti-dipeptidyl peptidase-4 (DDP-4) inhibitor
Sponsors
Nagasaki University Graduate School of Biomedical Sciences
1. Department of Metabolism/Diabetes and Clinical Nutrition, Nagasaki University Hospital 2. Department of Ophthalmology, Nagasaki University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetic patients who meet the following requirements 1) Diabetic retinopathy requiring treatment 2) 6.9%<=HbA1c<=11.0% 3) No prior treatment using DDP-4 inhibitor 4) No change of oral hypoglycemic drugs for 3 months prior 2. Patients over 20 years-old. 3. Patients who have been informed and have understood the full explanation of this study, and have agreed and given prior written consent.
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes, diabetic ketoacidosis or diabetic coma 2. Severe liver or kidney dysfunction 3. Severe infection or traumatic injury 4. In a perioperative period of major surgery 5. Anti-glutamic acid decarboxylase (GAD) antibody>=10U/ml 6. Poorly controlled hypertension; systolic blood pressure>=160mmHg or diastolic blood pressure>=100mmHg 7. Pregnant female, female with possibility of pregnancy and breast-feeding female 8. History of hypersensitivity to targeted medication 9. History of severe cardiovascular or cerebrovascular disease in 6 months 10. Any other factors that may disqualify the patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| chorioretinal blood flow | — |
Secondary
| Measure | Time frame |
|---|---|
| best corrected visual acuity, intraocular pressure, central retinal thickness, HbA1c, fasting blood glucose | — |
Countries
Japan
Contacts
Public ContactYuki Maekawa
Nagasaki University Graduate School of Biomedical Sciences Department of Ophthalmology & Visual Sciences
Outcome results
None listed